Cholesterol Lowering Drugs Market to Reach $35.8 Billion by 2035

Cholesterol Lowering Drugs market was valued at $23.2 billion in 2025 and is expected to reach $35.8 billion by 2035, registering a CAGR of 4.5% during the forecast period from 2026 to 2035. The market is being driven by a sustained and growing prevalence of high blood cholesterol, which is a major risk factor for cardiovascular disease globally. Recent public health data from the US indicate that the prevalence of self?reported high blood cholesterol among adults increased by 13.7?% from 2019 to 2023, signaling that more people are aware of and managing elevated cholesterol levels, which in turn supports demand for pharmaceutical interventions.? At the same time, an estimated 86?million US adults have total cholesterol above 200?mg/dL, with nearly 25?million having levels above 240?mg/dL, underscoring a large population in need of lipid?lowering therapies.? This heightened disease burden drives physicians to prescribe statins, PCSK9 inhibitors, and newer biologics more frequently, expanding market adoption. Enhanced screening practices and broader guideline endorsements for early cholesterol management have also contributed to increased drug utilization. These factors collectively reinforce sustained growth in the global cholesterol?lowering drugs market as clinicians and patients prioritize long?term cardiovascular risk reduction.

Browse the full report description of “Cholesterol Lowering Drugs Market Size, Share & Trends Analysis by Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Fibrates, Cholesterol Absorption Inhibitors, Combination Therapy, and Others), by Indication (Hypercholesterolemia, Cardiovascular Risk Reduction / Atherosclerosis, Hypertriglyceridemia), by Route of Administration (Oral, and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/cholesterol-lowering-drugs-market

Key Findings Supporting the Driver

• Self?reported high blood cholesterol prevalence increased 13.7?% from 2019 to 2023 among US adults, indicating rising disease burden and treatment demand.?
• Approximately 86?million US adults had total cholesterol above 200?mg/dL, suggesting substantial unmet need for lipid?lowering therapy.?
• Nearly one?quarter of adults have total cholesterol levels above 240?mg/dL, a threshold associated with elevated cardiovascular risk.?
• Data show 25.5?% of adults had LDL cholesterol ?130?mg/dL, reinforcing the clinical need for pharmacologic intervention.?
• High cholesterol is asymptomatic, making medical screening and preventive pharmaceutical management essential in large populations.?

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Drug Class
  • Indication
  • Route of Administration
  • Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – Amgen Inc., AstraZeneca plc, Novartis AG, Pfizer Inc., Sanofi S.A., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Cholesterol Lowering Drugs Market Report Segment

By Drug Class

• Statins
• PCSK9 Inhibitors
• Bile Acid Sequestrants
• Fibrates
• Cholesterol Absorption Inhibitors
• Combination Therapy
• Others

By Indication

• Hypercholesterolemia
• Cardiovascular Risk Reduction / Atherosclerosis
• Hypertriglyceridemia

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Cholesterol Lowering Drugs Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/cholesterol-lowering-drugs-market